Investigational drug · Phase 3
CMS-D001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "CMS-D001"
First trial start
2026
Mar 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CMS-D001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Plaque Psoriasis
- Moderate to Severe Atopic Dermatitis
Approved drugs for the same conditions: Plaque psoriasis · Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "CMS-D001" as an intervention, largest first.
- A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type PsoriasisPivotal-lookingNot yet recruiting
Dermavon Holdings LimitedIndustry
NCT07432854 · 540 participants (planned) · Start Mar 3, 2026 · Primary completion Feb 29, 2028
Drug: CMS-D001 50mg; CMS-D001 100mg and 1 more · For: Moderate to Severe Plaque Psoriasis
Sites: Bengbu, China; Wuhu, China; Guangzhou, China · 21 sites in all
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Dermavon Holdings LimitedIndustry
NCT07465120 · 160 participants (planned) · Start Mar 20, 2026 · Primary completion Jan 31, 2027
Drug: CMS-D001 50mg; CMS-D001 100mg and 2 more · For: Moderate to Severe Atopic Dermatitis
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Moderate to Severe Plaque Psoriasis
- SYHX1901Phase 32 trials
CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata
- WD-890Phase 32 trials
Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis
- SHR-1139Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum
- HS-20118Phase 21 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.